FOLH1 and prostate carcinoma: The earliest PSMA-targeted radioimmunoconjugate designed for prostate cancer patients was based on the 7E11 murine mAb (7E11/CYT-356, capromab pentide) labeled with the γ-emitter indium-111 (111In) [147].